Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/13653
Increased rate of FEV1 decline in HIV patients despite effective treatment with HAART
Identifiers
ISSN: 1932-6203
WOS ID: 000532653400037
Scopus EID: 2-s2.0-85074252861
PMID: 31661533
Embase PUI: L2003581522
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordPublication date
2019-10-29Document type
research articleCitation
Sampériz Abad G, Fanjul F,Valera Felices JL, Lopez Zamora M, Rios Olivencia A, Peñaranda Vera M, et al. Increased rate of FEV1 decline in HIV patients despite effective treatment with HAART. PLoS One. 2019 Oct 29;14(10):e0224510.Abstract
Introduction Previous studies have reported that the rate of FEV1 decline over time is increased in HIV patients but the mechanisms underlying this observation are unclear. Since current HIV treatment with Highly Active Antiretroviral Therapy (HAART) results in very good immuneviral control, we hypothesized that HAART should normalize the elevated rate of FEV1 decline previously reported in HIV patients if it was somehow related to the immune alterations caused by HIV, particularly in never smokers or quitters, since smoking is a well established risk factor for accelerated FEV1 decline in the general population. Methods We explored this hypothesis in a prospectively recruited cohort of 188 HIV (smoker and non-smoker) patients treated with HAART in Palma de Mallorca (Spain) and followed-up for 6 years. The cross-sectional characteristics of this cohort have been published elsewhere. Results We found that: (1) HAART resulted in good immune-viral control; (2) the rate of FEV1 decline remained abnormally elevated, even in non-smokers and quitters; and, (3) alcohol abuse during follow-up was related to FEV1 decline in these patients. Discussion Despite adequate immune-viral control by HAART, lung function decline remains increased in most HIV patients, even in non-smokers and quitters. Alcohol abuse is a preventable risk factor to decrease the accelerated FEV1 decline in this population.
Publisher version
https://dx.doi.org/10.1371/journal.pone.0224510MeSH
Viral LoadCD4 Lymphocyte Count
Spain
Adult
DNA-Binding Proteins
Follow-Up Studies
Humans
Smoking
Anti-HIV Agents
Antiretroviral Therapy, Highly Active
Middle Aged
Cross-Sectional Studies
HIV Infections
Male
Prospective Studies
Female
Risk Factors
Treatment Outcome
HIV-1
Cohort Studies
Transcription Factors
DeCS
VIH-1Estudios de Cohortes
Resultado del Tratamiento
Factores de Transcripción
Femenino
Infecciones por VIH
Terapia Antirretroviral Altamente Activa
Masculino
Estudios de Seguimiento
Proteínas de Unión al ADN
Fumar
Estudios Transversales
Factores de Riesgo
Fármacos Anti-VIH
Humanos
Persona de Mediana Edad
Estudios Prospectivos
Recuento de Linfocito CD4
Adulto
España
Carga Viral
This item appears in following Docusalut collections
Hospital Universitario Son Espases - HUSE > Comunicación científicaInstituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científica